Biopharma
|
July 2, 2025
mAbxience Announces European Commission Approval of Denosumab Biosimilars
mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce® and Izamby®.